ClinicalTrials.Veeva

Menu

Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab (EXPRIME)

U

University Hospital, Lille

Status

Completed

Conditions

Autoimmune Diseases

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03778840
2018-A00188-47 (Other Identifier)
2018_06

Details and patient eligibility

About

Rituximab is a very effective drug used to treat many inflammatory diseases. These diseases include, for example, rheumatoid arthritis, multiple sclerosis and systemic autoimmune diseases.

The major drawback of this drug is the risk of infection, which are favored by the direct effect of rituximab on the immune system. The risk of infection is one of the major reason not to prescribe or withdraw rituximab in several patients. However, many questions remain unanswered regarding the proportion and risk factors of infection or immunodeficiency induced by rituximab. Better understanding of these issues will help prescribing rituximab and properly monitor patients during their treatment. Moreover, as treatment with substitutive immunoglobulins might be a solution to decrease the risk of infections in those patients, it is very important to better characterize the risk and risk factors of rituximab-associated infection. The present study aims to answer these questions.

Enrollment

73 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient initiating treatment with RTX, delivered by the central pharmacy of Lille University Hospital
  • Inpatient or outpatient at Lille University Hospital (in one of the following departments: internal medicine, rheumatology, neurology, dermatology, pneumology) and monitored every three months as part of routine care (as part of the surveillance of induction of RTX treatment)
  • Patient with one of the following autoimmune diseases, defined by international criteria

Exclusion criteria

  • Treatment with rituximab for a malignancy or a transplant reject
  • Pregnant or lactating women
  • People in emergency
  • Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system, refusal to sign consent
  • Persons deprived of their liberty
  • People unable to consent

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems